---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005069"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:38:40.238353+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Syndax Q4 2022 net loss $39.2M; revumenib topline data expected Q3 2023

## Summary
- Net loss of $39.2M ($0.62 per share) for Q4 2022 vs net gain of $96.2M ($1.81) in Q4 2021.
- Cash and investments $481.3M as of Dec 31, 2022; raised $162M from December stock offering.
- Revumenib topline data from AUGMENT-101 KMT2Ar cohort expected Q3 2023; NDA filing by year-end 2023.
- Axatilimab topline data from pivotal AGAVE-201 expected mid-2023; BLA filing by year-end 2023.
- Guidance: Full year 2023 total operating expenses $225-240M, R&D $160-175M.

## SEC filing metadata
- accession: 0000950170-23-005069
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005069/0000950170-23-005069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005069/sndx-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005069
- JSON: https://secwatch.observer/filing/0000950170-23-005069.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005069.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005069/0000950170-23-005069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.